Trials / Recruiting
RecruitingNCT04903951
Impact of Early Ventilation in Stroke Outcomes in Patients With Sleep Apnea After First Ever Stroke
A Single-center, Randomized, Open Label, Parallel Arm, Prospective Study to Evaluate the Impact of Early Ventilation in Stroke Outcomes in Patients With Sleep Apnea After First Ever Stroke
- Status
- Recruiting
- Phase
- Phase 2
- Study type
- Interventional
- Enrollment
- 90 (estimated)
- Sponsor
- Philips Portuguesa S.A. · Industry
- Sex
- All
- Age
- 18 Years – 80 Years
- Healthy volunteers
- Not accepted
Summary
To evaluate the impact of early ventilation in stroke outcomes in patients with sleep apnea and first ever stroke, 1 month after stroke.
Detailed description
Single-center, randomized, open label, parallel arm, prospective study in patients with sleep apnea after first-ever stroke. The study will consist of screening, baseline assessment, interventional period (consisting of a treatment period and follow-up visits), and a follow-up phone call. Patients will be randomly assigned to ASV (active) or control groups, within 4 days after the PSG II and will start the respective intervention in the same day. Patients assigned to the active group will receive ventilatory support with ASV (DreamStation BiPAP autoSV®) during diurnal and nocturnal sleep, from study randomization until clinically indicated. Patients assigned to control group will receive best medical treatment for stroke alone, including rehabilitation.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DEVICE | Adaptive Servoventilation (ASV) therapy | Patients assigned to the active group will receive ventilatory support with ASV (DreamStation BiPAP autoSV®) during diurnal and nocturnal sleep, from study randomization until clinically indicated |
| OTHER | Best medical treatment | Best medical treatment for stroke, including rehabilitation |
Timeline
- Start date
- 2024-02-27
- Primary completion
- 2025-08-01
- Completion
- 2025-08-01
- First posted
- 2021-05-27
- Last updated
- 2024-08-12
Locations
1 site across 1 country: Portugal
Source: ClinicalTrials.gov record NCT04903951. Inclusion in this directory is not an endorsement.